Angelika Hammerer-Lercher

Dr. Angelika Hammerer-Lercher

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2026 in European Heart Journal
Verified
Journal Article
Closed access
NGNoemi Glarner
Noemi Glarner
CPChristian Puelacher
Christian Puelacher
DGDanielle M Gualandro
Danielle M Gualandro
MPMirjam Pargger
Mirjam Pargger
KDKoray Durak
Koray Durak
CMChristian Mueller
Christian Mueller
Background and Aims: Peri-operative myocardial infarction/injury (PMI) is a common cardiac complication following non-cardiac surgery. It remains unclear whether involvement of cardiologists in the management of patients developing PMI improves outcomes. Methods: This multicentre, prospective study included high-risk patients undergoing non-cardiac surgery, eligible for the institutional PMI active surveillance and response programme. Due to staffing constraints, cardiologist evaluation of patients with PMI was inconsistently available on weekends, on public holidays, or when care for more urgent patients had to be prioritized, allowing a comparison between patients receiving cardiologist evaluation and those who did not. The primary endpoint was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, acute heart failure, and life-threatening arrhythmia at 365 days. The secondary endpoint was all-cause death at 365 days. Cox proportional hazards models were used to evaluate the association between cardiologist evaluation and outcomes. Results: Among 14 294 patients, 1048 developed PMI and were eligible for this analysis, of whom 614 patients (58.6%) received post-operative cardiologist evaluation. Baseline characteristics were similar between groups. After adjustment, cardiologist evaluation was independently associated with lower risk of major adverse cardiac events (adjusted hazard ratio .54, P = .001) and all-cause death (adjusted hazard ratio .65, P = .037) at 365 days. Sensitivity analyses confirmed these findings. Patients receiving cardiology evaluation were more likely to undergo non-invasive cardiac imaging and to receive dual antiplatelet and statin therapy. Conclusions: Cardiologist evaluation of patients with PMI following major non-cardiac surgery was associated with a reduced risk of major adverse cardiac events and all-cause mortality at 365 days after surgery, suggesting that interdisciplinary management may improve post-operative outcomes.

1 January 2015 in Disease Markers
Verified
Journal Article
Open access
PDF file
SRSebastian Johannes Reinstadler
Sebastian Johannes Reinstadler
HFHans Josef Feistritzer
Hans Josef Feistritzer
GKGert Klug
Gert Klug
AMAgnes Mayr
Agnes Mayr
LHLuc Huybrechts
Luc Huybrechts
BMBernhard Metzler
Bernhard Metzler
Aim. Increased aortic stiffness might adversely affect cardiac structure, function, and perfusion. Release of biomarkers of hemodynamic stress is thought to be enhanced by these alterations. We aimed to evaluate the association between biomarkers of hemodynamic stress and aortic stiffness assessed at a chronic stage after ST-segment elevation myocardial infarction (STEMI).Methods. Fifty-four patients four months after STEMI were enrolled in this cross-sectional, single-center study. N-terminal pro–B-type natriuretic peptide (NT-proBNP), mid-regional pro–A-type natriuretic peptide (MR-proANP), and mid-regional proadrenomedullin (MR-proADM) levels were measured by established assays. Aortic stiffness was assessed by the measurement of pulse wave velocity using phase-contrast cardiovascular magnetic resonance.Results. NT-proBNP, MR-proANP, and MR-proADM concentrations were all correlated with aortic stiffness in univariate analysis (r=0.378,r=0.425, andr=0.532; allP<0.005, resp.). In multiple linear regression analysis, NT-proBNP (β=0.316,P=0.005) and MR-proADM (β=0.284,P<0.020) levels were associated with increased aortic stiffness independently of age, blood pressure, and renal function. NT-proBNP was the strongest predictor for high aortic stiffness (area under the curve: 0.82, 95% CI 0.67–0.96).Conclusion. At a chronic stage after STEMI, concentrations of biomarkers for hemodynamic stress, especially NT-proBNP, are positively correlated with aortic stiffness. These biomarkers might also be useful as predictors of high aortic stiffness after STEMI.

19 October 2023 in Clinical Nutrition
Verified
Journal Article
Open access
KSKatja Angela Schönenberger
Katja Angela Schönenberger
CSChristoph Saxer
Christoph Saxer
PNPeter Neyer
Peter Neyer
VHValentina Viola Huwiler
Valentina Viola Huwiler
EREmilie Reber
Emilie Reber
SMStefan Mühlebach
Stefan Mühlebach
Parenteral nutrition (PN) can lead to high or even toxic exposure to aluminum (Al). We aimed to quantify concentrations of Al and other chemical elements of all-in-one (AIO) PN admixtures for adults prepared from commercial multichamber bags (Olimel® 5.7%, Omegaflex® special, SmofKabiven®, all with and without electrolytes) and vitamin and trace element additives over a 48-h period. Secondly, we determined the level of Al contamination resulting from admixing and infusion set use. We used dynamic reaction cell and kinetic energy discrimination inductively coupled plasma mass spectrometry (ICP-MS) to quantify Al, arsenic (As), cadmium (Cd), cobalt (Co), chromium (Cr), copper (Cu), iron (Fe), magnesium (Mg), manganese (Mn), molybdenum (Mo), nickel (Ni), antimony (Sb), selenium (Se), tin (Sn), vanadium (V), and zinc (Zn) in AIO PN admixtures. We extracted samples for analysis via the bag injection ports and infusion sets over a 48-h period after admixing. We compared the measured Al concentrations of AIO PN admixtures with calculated values based on the measured concentrations of individual chamber contents and additives. Mean (standard deviation) baseline Al concentrations in AIO PN admixtures ranged from 10.5 (0.5) to 59.3 (11.4) μg/L and decreased slightly over the 48 h (estimate [standard error] -0.09 [0.02] μg/L/hour, p <0.001). Thus, certain products exceeded the widely accepted limit of 25 μg/L. There was no significant difference in Al concentrations between samples extracted via the bag injection ports or infusion sets (p = 0.33), nor between measured and calculated Al concentrations of AIO PN admixtures (p = 0.91). Because certain commercially available PN admixtures for adults proved to contain excessively high levels of Al in our study, regulations and corresponding quality requirements at the authority level (e.g., Pharmacopoeia and regulatory authorities) are urgently required. Our results showed that the PN handling process (admixing and supplementing additives) or the materials of the infusion set did not lead to additional Al contamination to any extent. Moreover, calculated Al concentrations of AIO PN admixtures derived from individual chamber contents and additives are valid.

1 December 2020 in Clinica Chimica Acta
Verified
Journal Article
Closed access
AHAngelika Hammerer-Lercher
Angelika Hammerer-Lercher
DGDamien Gruson
Damien Gruson
SSSanja Stankovic
Sanja Stankovic
PCPaul Collinson
Paul Collinson
JSJanne Suvisaari
Janne Suvisaari
PLPaivi Laitinen
Paivi Laitinen

15 April 2024 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
NGNoemi Glarner
Noemi Glarner
CPChristian Puelacher
Christian Puelacher
DGDanielle M. Gualandro
Danielle M. Gualandro
MPMirjam Pargger
Mirjam Pargger
GHGabrielle Huré
Gabrielle Huré
KMKathrin Meissner
Kathrin Meissner

24 March 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CGChun-Jie Guo
Chun-Jie Guo
UAUma P. Arora
Uma P. Arora
WXWanying Xu
Wanying Xu
XCXiaoheng Cheng
Xiaoheng Cheng
LCLiam D. Cato
Liam D. Cato
VSVijay G. Sankaran
Vijay G. Sankaran
Human genetic studies have identified key regulators of fetal hemoglobin (HbF) expression, including BCL11A, resulting in therapeutic advances. Yet the mechanisms by which HbF expression is activated remain incompletely understood. Here, we conduct a multi-ancestry genome-wide association study of HbF levels in 28,237 individuals that identifies 131 conditionally-independent associations across 12 genomic regions. In one previously uncharacterized associated region, the high-HbF-linked causal variant, rs1010474-C, reduces BACH2 expression and elevates HbF levels. Direct perturbation or inhibition of BACH2 elevates HbF expression. Mechanistically, BACH2 restrains activation of the HbF-encoding γ -globin genes, while loss of BACH2 enhances NRF2 chromatin occupancy and promotes activation foci formation at the γ -globin genes. BACH2 and NRF2 binding motifs in the γ -globin promoters, while overlapping, can be selectively edited to activate or repress γ -globin, respectively, and function independently of BCL11A. These findings illustrate how human genetic variation continues to advance our knowledge of therapeutically-relevant regulatory mechanisms underlying HbF expression.